W
Willard Lew
Researcher at Sunesis Pharmaceuticals
Publications - 58
Citations - 3838
Willard Lew is an academic researcher from Sunesis Pharmaceuticals. The author has contributed to research in topics: Neuraminidase & Orthomyxoviridae. The author has an hindex of 25, co-authored 57 publications receiving 3309 citations.
Papers
More filters
Journal ArticleDOI
Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys
Travis K. Warren,Robert Jordan,Michael K. Lo,Adrian S. Ray,Richard L. Mackman,Veronica Soloveva,Dustin Siegel,Michel Perron,Roy Bannister,Hui Hon Chung,Nate Larson,Robert G. Strickley,Jay Wells,Kelly S. Stuthman,Sean A. Van Tongeren,Nicole L. Garza,Ginger Donnelly,Amy C. Shurtleff,Cary Retterer,Dima N. Gharaibeh,Rouzbeh Zamani,Tara Kenny,Brett P. Eaton,Elizabeth C. Grimes,Lisa S. Welch,Laura Gomba,Catherine L. Wilhelmsen,Donald K. Nichols,Jonathan E. Nuss,Elyse R. Nagle,Jeffrey R. Kugelman,Gustavo Palacios,Edward Doerffler,Sean Neville,Ernest Carra,Michael O. Clarke,Lijun Zhang,Willard Lew,Bruce Ross,Queenie Wang,Kwon Soo Chun,Lydia Wolfe,Darius Babusis,Yeojin Park,Kirsten M. Stray,Iva Trancheva,Joy Y. Feng,Ona Barauskas,Yili Xu,Pamela Wong,Molly R. Braun,Mike Flint,Laura K. McMullan,Shan Shan Chen,Rachel Fearns,S. Swaminathan,Douglas L. Mayers,Christina F. Spiropoulou,William A. Lee,Stuart T. Nichol,Tomas Cihlar,Sina Bavari +61 more
TL;DR: These results show the first substantive post-exposure protection by a small-molecule antiviral compound against EBOV in nonhuman primates, and the broad-spectrum antiviral activity of GS-5734 in vitro against other pathogenic RNA viruses, including filoviruses, arenavirus, and coronavirus suggests the potential for wider medical use.
Journal ArticleDOI
Discovery and Synthesis of a Phosphoramidate Prodrug of a Pyrrolo[2,1-f][triazin-4-amino] Adenine C-Nucleoside (GS-5734) for the Treatment of Ebola and Emerging Viruses
Dustin Siegel,Hui Hon Chung,Edward Doerffler,Michael O'neil Hanrahan Clarke,Kwon Soo Chun,Lijun Zhang,Sean Neville,Ernest Carra,Willard Lew,Bruce Ross,Queenie Wang,Lydia Wolfe,Robert Jordan,Veronica Soloveva,John E. Knox,Jason K. Perry,Michel Perron,Kirsten M. Stray,Ona Barauskas,Joy Y. Feng,Yili Xu,Gary Lee,Arnold L. Rheingold,Adrian S. Ray,Roy Bannister,Robert G. Strickley,S. Swaminathan,William A. Lee,Sina Bavari,Tomas Cihlar,Michael K. Lo,Travis K. Warren,Richard L. Mackman +32 more
TL;DR: A robust diastereoselective synthesis provided sufficient quantities of 4b to enable preclinical efficacy in a non-human-primate EBOV challenge model and structure activity relationships established that the 1′-CN group and C-linked nucleobase were critical for optimal anti-EBOV potency and selectivity against host polymerases.
Journal ArticleDOI
Oral Administration of a Prodrug of the Influenza Virus Neuraminidase Inhibitor GS 4071 Protects Mice and Ferrets against Influenza Infection
Dirk B. Mendel,Chun Y. Tai,Paul A. Escarpe,Weixing Li,Robert W. Sidwell,John H. Huffman,Clive Sweet,Kenneth J. Jakeman,James R. Merson,Steven A. Lacy,Willard Lew,Matthew A. Williams,Lijun Zhang,Ming S. Chen,Norbert Bischofberger,Choung U. Kim +15 more
TL;DR: The results indicate that GS 4104 is a novel, orally active antiviral agent with the potential to be used for the prophylaxis and treatment of influenza A and B virus infections.
Journal ArticleDOI
Discovery and Development of GS 4104 (oseltamivir) An Orally Active Influenza Neuraminidase Inhibitor
TL;DR: The design, discovery, and development of oseltamivir as an oral therapeutic to treat influenza infection is summarized.
Journal ArticleDOI
Identification of GS 4104 as an Orally Bioavailable Prodrug of the Influenza Virus Neuraminidase Inhibitor GS 4071
Weixing Li,Paul A. Escarpe,Eugene J. Eisenberg,Kenneth C. Cundy,Clive Sweet,Kenneth J. Jakeman,James R. Merson,Willard Lew,Matthew A. Williams,Lijun Zhang,Choung U. Kim,Norbert Bischofberger,Ming S. Chen,Dirk B. Mendel +13 more
TL;DR: Results demonstrate that GS 4104 is an orally bioavailable prodrug of GS 4071 in animals and that it has the potential to be an oral agent for the prevention and treatment of influenza A and B virus infections in humans.